JP2023544387A5 - - Google Patents

Info

Publication number
JP2023544387A5
JP2023544387A5 JP2023520305A JP2023520305A JP2023544387A5 JP 2023544387 A5 JP2023544387 A5 JP 2023544387A5 JP 2023520305 A JP2023520305 A JP 2023520305A JP 2023520305 A JP2023520305 A JP 2023520305A JP 2023544387 A5 JP2023544387 A5 JP 2023544387A5
Authority
JP
Japan
Prior art keywords
gdf3
level
patient
risk
cardiac remodeling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023520305A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023544387A (ja
JP7823034B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/077267 external-priority patent/WO2022073915A1/en
Publication of JP2023544387A publication Critical patent/JP2023544387A/ja
Publication of JP2023544387A5 publication Critical patent/JP2023544387A5/ja
Application granted granted Critical
Publication of JP7823034B2 publication Critical patent/JP7823034B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023520305A 2020-10-05 2021-10-04 虚血後の心臓リモデリングにおけるバイオマーカー及びバイオターゲットとしてのｇｄｆ３ Active JP7823034B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20306156 2020-10-05
EP20306156.9 2020-10-05
PCT/EP2021/077267 WO2022073915A1 (en) 2020-10-05 2021-10-04 Gdf3 as biomarker and biotarget in post-ischemic cardiac remodeling

Publications (3)

Publication Number Publication Date
JP2023544387A JP2023544387A (ja) 2023-10-23
JP2023544387A5 true JP2023544387A5 (https=) 2024-08-14
JP7823034B2 JP7823034B2 (ja) 2026-03-03

Family

ID=72944085

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023520305A Active JP7823034B2 (ja) 2020-10-05 2021-10-04 虚血後の心臓リモデリングにおけるバイオマーカー及びバイオターゲットとしてのｇｄｆ３

Country Status (4)

Country Link
US (1) US20230375571A1 (https=)
EP (1) EP4226160A1 (https=)
JP (1) JP7823034B2 (https=)
WO (1) WO2022073915A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114859061B (zh) * 2022-05-06 2024-10-18 华中科技大学同济医学院附属协和医院 预测心梗患者有害心室重塑和免疫治疗疗效的标志物及其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5808007A (en) * 1993-01-12 1998-09-15 The Johns Hopkins University School Of Medicine Growth differentiation factor-3
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
EP1771557B1 (en) * 2004-06-24 2014-12-31 Acceleron Pharma Inc. GDF3 Propeptides and Related Methods
US7611834B2 (en) 2005-09-30 2009-11-03 Sandia Corporation Methods and devices for protein assays
US20090082552A1 (en) 2007-09-26 2009-03-26 Magdalena Bynum Microfluidic protein assay
EP2632950B1 (en) * 2010-10-26 2018-08-22 UMC Utrecht Holding B.V. Antibody binding to fibronectin-eda for preventing myocardial infarction-related complications
WO2013137715A1 (en) * 2012-03-16 2013-09-19 Umc Utrecht Holding B.V. Biomarkers for adverse cardiac remodeling
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2017189605A1 (en) * 2016-04-25 2017-11-02 Siemens Healthcare Diagnostics Inc. Diagnostic method(s) for detecting and treating post-infarct myocardium remodeling and diffuse myocardial fibrosis
CA3052625A1 (en) * 2017-02-06 2018-08-09 Acceleron Pharma Inc. Compositions and methods for treating heart failure
EP3409778A1 (en) * 2017-05-31 2018-12-05 Medizinische Hochschule Hannover Lncrnas gadlor 1 and 2 for use in treating and preventing cardiac remodelling
JP2022512648A (ja) * 2018-10-09 2022-02-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 心筋線維化の処置のためのαＶ－インテグリン（ＣＤ５１）阻害剤の使用

Similar Documents

Publication Publication Date Title
JP5978128B2 (ja) 線維症バイオマーカアッセイ
Schmidt et al. Stretch-activated two-pore-domain (K2P) potassium channels in the heart: Focus on atrial fibrillation and heart failure
ES2573943T3 (es) Monitorización e inhibición de infección por virus de la inmunodeficiencia humana mediante modulación del desencadenamiento dependiente de HMGB1 de la replicación y persistencia de VIH-1
Barascuk et al. A MMP derived versican neo-epitope is elevated in plasma from patients with atherosclerotic heart disease
JP2015530868A5 (https=)
Zhong et al. Extracellular HSP90α promotes cellular senescence by modulating TGF‐β signaling in pulmonary fibrosis
Pires et al. A block in the road to fertility: autoantibodies to heat-shock protein 90-β in human ovarian autoimmunity
JP5863660B2 (ja) Ｇｓｔｐ１の使用
JP2023544387A5 (https=)
ES2201929B1 (es) Anticuerpos policlonales, metodo de preparacion y uso de los mismos.
JP6080850B2 (ja) 改善されたワクチン診断法
JP2014516155A (ja) 早期関節リウマチの診断のための方法
Du et al. Autoantibodies against β1‐Adrenoceptor exaggerated ventricular Remodeling by inhibiting CTRP9 expression
Ishikawa et al. Expression of parathyroid hormone-related protein in human and experimental atherosclerotic lesions: functional role in arterial intimal thickening
JP4567890B2 (ja) メグシンタンパク質の検出方法およびその用途
JP2009529659A5 (https=)
JP5364086B2 (ja) 変形性関節症と関節リウマチ及び無病状態とを鑑別するための軟骨中間層タンパク質２ｃ１及びその使用
JP2009529659A (ja) 栄養膜細胞の細胞死、分化、浸潤、および／または細胞融合および代謝回転に関連する状態の診断用組成物および治療方法
TWI744777B (zh) 一種類風溼關節炎自體抗體結合的胜肽及其應用
US20090317843A1 (en) Method for measuring plasma levels of long pentraxin ptx3
CN101466732A (zh) Iv型胶原样免疫反应性多肽
KR20200135994A (ko) 심장 근육 손상의 진단 방법
KR101349198B1 (ko) 항균성 펩티드의 발현을 회복시키기 위한 스핑고실포스포릴콜린 길항제의 용도
JP2023514738A5 (https=)
KR102762864B1 (ko) 히스톤 펩타이드를 유효성분으로 포함하는 관절염 진단용 조성물